Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

This study is testing a new type of CAR-T cell therapy — where immune cells are genetically engineered to attack a specific target (CD117) found on leukemia cells — in people with relapsed or refractory acute myeloid leukemia (AML) who have not responded to standard treatments. **You may be eligible if...** - You have been confirmed to have CD117-positive AML that has returned after treatment or did not respond to at least two rounds of standard chemotherapy - You have no other available standard treatment options - Your liver, kidney, and heart function meet required levels - Your general health status (ECOG) is 0, 1, or 2 - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have a history of seizures or significant neurological disease - You have a prolonged heart QT interval or serious heart disease - You have an active uncontrolled infection - You have active hepatitis B or C - You have previously received gene therapy - You are infected with HIV/AIDS - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.